Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanisms of G2 arrest in response to overexpression of p53.
Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS, Stark GR. Taylor WR, et al. Among authors: deprimo se. Mol Biol Cell. 1999 Nov;10(11):3607-22. doi: 10.1091/mbc.10.11.3607. Mol Biol Cell. 1999. PMID: 10564259 Free PMC article.
Regulation of p53 expression by the RAS-MAP kinase pathway.
Agarwal ML, Ramana CV, Hamilton M, Taylor WR, DePrimo SE, Bean LJ, Agarwal A, Agarwal MK, Wolfman A, Stark GR. Agarwal ML, et al. Among authors: deprimo se. Oncogene. 2001 May 3;20(20):2527-36. doi: 10.1038/sj.onc.1204353. Oncogene. 2001. PMID: 11420662
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P, Schappin R, Florencia EF, van Heeswijk B, Prens LM, van der Zee HH, Prens EP, van Straalen KR, Horváth B. Dudink K, et al. Among authors: deprimo se. Br J Dermatol. 2023 Apr 20;188(5):601-609. doi: 10.1093/bjd/ljad010. Br J Dermatol. 2023. PMID: 36811949 Clinical Trial.
Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study.
Boyle DL, DePrimo SE, Calderon C, Chen D, Dunford PJ, Barchuk W, Firestein GS, Thurmond RL. Boyle DL, et al. Among authors: deprimo se. Inflamm Res. 2019 Apr;68(4):261-274. doi: 10.1007/s00011-019-01218-y. Epub 2019 Feb 9. Inflamm Res. 2019. PMID: 30739130 Clinical Trial.
Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.
Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, DePrimo SE, Muñoz-Elías EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA. Loesche MA, et al. Among authors: deprimo se. J Invest Dermatol. 2018 Sep;138(9):1973-1981. doi: 10.1016/j.jid.2018.03.1501. Epub 2018 Mar 17. J Invest Dermatol. 2018. PMID: 29559344 Free article. Clinical Trial.
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. Zurita AJ, et al. Among authors: deprimo se. Br J Cancer. 2015 Mar 31;112(7):1199-205. doi: 10.1038/bjc.2015.73. Br J Cancer. 2015. PMID: 25756398 Free PMC article. Clinical Trial.
31 results